(→Niskocząsteczkowe inhibitory domeny kinazowej JAK2) |
|||
Linia 14: | Linia 14: | ||
|- | |- | ||
|1 | |1 | ||
− | |AG490 | + | |AG490<br>(EGFR, PDGFR) |
− | (EGFR, | ||
− | PDGFR) | ||
|tyrphostin | |tyrphostin | ||
|36.448145.3 | |36.448145.3 | ||
− | |B-precursor (KOCL-33,-45,-50,-69,KOPN-30bi,-55bi,-57bi,-72bi,KOPN-32,-62,-84,NALM 6) | + | |B-precursor (KOCL-33,-45,-50,-69,KOPN-30bi,-55bi,-57bi,-72bi,KOPN-32,-62,-84,NALM 6)<br>T-precursor (KOPT-K1,-5,-11,Jurkat)<br>Ba/F3:JAK2V617F<br>HEL (JAK2V617F)<br>SET-2 (JAK2V617F/wt)<br>XG-1<br>XG-2<br>U266<br>MDAH2774<br>Caov-3<br>MDA-MB-468 |
− | T-precursor (KOPT-K1,-5,-11,Jurkat) | + | |-<br>-<br>1.0<br>>20.0<br>>20.0<br>14.8<br>12.9<br>26.0<br>-<br>-<br>- |
− | Ba/F3:JAK2V617F | + | |Gazit et al. 1989,1991<br>Meydan et al. 1996<br>Vos et al. 2000<br>Miyamoto et al. 2001<br>Burke et al. 2001<br>Duhé et al. 2002<br>Reddy et al. 2010<br>Jatiani et al. 2010 |
− | HEL (JAK2V617F) | ||
− | SET-2 (JAK2V617F/wt) | ||
− | XG-1 | ||
− | XG-2 | ||
− | U266 | ||
− | MDAH2774 | ||
− | Caov-3 | ||
− | MDA-MB-468 | ||
− | |-1.0>20.0>20. | ||
− | |Gazit et al. 1989,1991 | ||
− | Meydan et al. 1996 | ||
− | Vos et al. 2000 | ||
− | Miyamoto et al. 2001 | ||
− | Burke et al. 2001 | ||
− | Duhé et al. 2002 | ||
− | Reddy et al. 2010 | ||
− | Jatiani et al. 2010 | ||
|} | |} | ||
Wersja z 12:47, 16 maj 2014
Niskocząsteczkowe inhibitory domeny kinazowej JAK2
Lp. | inhibitor (inne hamowane kinazy) |
klasa chemiczna | test enzym. | test komórkowy | literatura |
---|---|---|---|---|---|
IC50 (mM) | linia komórkowa | GI50 (mM) | |||
1 | AG490 (EGFR, PDGFR) |
tyrphostin | 36.448145.3 | B-precursor (KOCL-33,-45,-50,-69,KOPN-30bi,-55bi,-57bi,-72bi,KOPN-32,-62,-84,NALM 6) T-precursor (KOPT-K1,-5,-11,Jurkat) Ba/F3:JAK2V617F HEL (JAK2V617F) SET-2 (JAK2V617F/wt) XG-1 XG-2 U266 MDAH2774 Caov-3 MDA-MB-468 | |
Gazit et al. 1989,1991 Meydan et al. 1996 Vos et al. 2000 Miyamoto et al. 2001 Burke et al. 2001 Duhé et al. 2002 Reddy et al. 2010 Jatiani et al. 2010 |
2
LS104
(BCR-ABL)
tyrphostin
2.52
0.1-0.6
Ba/F3:EpoR,JAK2V617F
Ba/F3:EpoR,JAK2wt
HEL
1.5
10.0 Grunberger et al. 2003 Lipka et al. 2008 3 WP1066 tyrphostin - HEL 2.3 Verstovsek et al. 2008
4 ON044580 (BCR-ABL) a-benzoyl styryl benzyl sulfide 0.9-1.2 4.2 Ba/F3:JAK2V617F HEL SET-2 0.25 0.90 3.00 Reddy et al. 2010 Jatiani et al. 2010 Samanta et al. 2010 5 CEP701 (FLT3,JAK3) indolocarbazole 0.001 HEL 0.03-0.10 Hexner et al. 2008 Santos et al. 2010 6 Go6976 (JAK3, FLT3, PKCa,b1) indolocarbazole 0.13 32D 32D:TEL-JAK2 FDCP1 TF-1 Mo7E HEL 0.093 0.242 - - - - Grandage et al. 2006 7 TG02 (CDKs, FLT3) pyrimidine - HEL SET-2 Ba/F3:JAK2wt Ba/F3:JAK2V617F Karpas-1106P 32D 0.202 0.231 0.156 0.099 0.068 0.098 Goh et al. 2011 8 TG101209 (FLT3, RET, JAK3) pyrimidine 0.006 Ba/F3:JAK2V617F HEL multiple myeloma cell lines (RPMI8226, MM1S, OPM2, NCI-H929, Dox40, MM1R, LR5) 0.2 2-5 -
Pardanani et al. 2007
Wang and Fiskus et al. 2009
Ramkrishnan et al. 2010
9
TG101348
(FLT3,RET,JAK1,
JAK3,TYK2)
pyrimidine
0.003
Ba/F3:JAK2V617F
HEL
0.270
0.305
Wernig et al. 2008
Animesh et al. 2009
Pardanani et al. 2011
10
R723
(JAK3,TYK2,FLT3,
PRKD2,TBK1,SYK,
PAK4,DAPK3,PRKD1,MYLK2,PRKCN,
STK22D,IKBKE)
pyrimidine
0.002
Ba/F3:JAK2V617F
0.13-0.20
Shide et al. 2009
Shide et al. 2011
11
INCB018424
(JAK1,JAK3,TYK2)
pyrrolopyrimidine
0.0045
-
-
Verstovsek et al. 2008, 2010
Mesa 2010
12
INCB16562
(JAK1,JAK3)
pyrrolopyrimidine
0.0003
Ba/F3:JAK2V617F
Ba/F3:JAK2K539L
Ba/F3:MPLW515L
Ba/F3:TEL-JAK2
SET-2
UKE-1
0.177
0.406
0.600
0.168
0.046
0.573
Koppikar et al. 2010
13
CP690550
(JAK1,
JAK3,
TYK2)
pyrrolopyrimidine
0.0041
0.011
0.012
0.020
FDCP-EpoR,JAK2wt
FDCP-EpoR,JAK2V617F
2.1
0.25
Changelian et al. 2003
Chen et al. 2006
Clark et al. 2007
Manshouri et al. 2008
Meyer et al. 2010
Thoma et al. 2011
14
AZD1480
(JAK1,JAK3,TRKA,
AuroraA,FLT4,FGFR1,ARK5)
pyrazolopyrimidine
0.0004
0.003
Ba/F3:TEL-JAK2
SET-2
UKE1
HEL
0.06
0.016
0.054
0.39
Hedvat et al. 2009
Ioannidis et al. 2011
15
CYT387
(JAK1,TYK2,
CDK2/cyclinA,
JNK1,PRKCN,
PRKD1,ROCK2,TBK1)
aminopyrimidine
0.018
Ba/F3:EpoR,JAK2V617F
32D:EpoR,JAK2V617F
HEL
TF-1
U266
CHRF-288-11:JAK2T875N
Ba/F3:TEL-JAK2
0.5
1.5
1.5
1.25
0.75
0.001
0.724 Pardanani et al. 2009 Tyner et al. 2010 16 SGI1252 (JAK1,JAK3,TYK2, YES,FLT3,ABL,SRC, LCK) diaminopyrimidine 0.002 0.0197 FDCP-EpoR,JAK2wt FDCP-EpoR,JAK2V617F HEL SET-2 UKE-1 0.074 0.110 0.441 0.055 0.089 Olsen et al. 2008 Riaz Ahmed et al. 2011 17 SB1518 (FLT3,JAK1, JAK3,TYK2) aminopyrimidine macrocycle 0.023 0.019 Ba/F3:JAK2V617F HEL SET-2 Karpas-1106P U266 0.16 1.726 0.217 0.348 1.350 Hart et al. 2011 William et al. 2011 18 Z3 pyridine 15.0 28.0 HEL - Sayyah et al. 2008 19 25 (JAK1,GAK,YSK4) thienopyridine 0.002 Ba/F3:TEL-JAK2 (IC50) 1.62 Schenkel et al. 2011 20 65 (JAK1,cSRC,TRKA, ACK1,FMS,FYN,FLT3,HCK,RET,BMX,LYN, FGR,LCK,ARK5,BTK,YES,PTK5,TRKB, CaMKIId,g,PRK2,ARG,MLK1,ALK) pyridoindolcarboxamide 0.0008 irf1-bla HEL (IC50) 0.025 Lim et al. 2011 21 AT9283 (AuroraK,JAK3, FLT3,ABL) pyrazole benzimidazole 0.0012 HEL (JAK2V617F) SET-2 (JAK2V617F/wt) Ba/F3:ETV6-JAK2 Ba/F3-IL-3 TF-1-IL-3 CMK (JAK2A572V) 0.110 0.057 0.016 0.017 0.040 0.026 Howard et al. 2009 Dawson et al. 2010 22 AZ960 (TRKA,AuroraA, ARK5,ALK,CaMKII, FLT4,FGFR1,LIMK1, BrSK2,FAK) pyrazole nicotinonitrile 0.003 SET-2 (JAK2V617F/wt) Ba/F3:TEL-JAK2 HTLV-1 infected T cells (MT-1, MT-2) 0.033 0.025 -
Gozgit et al. 2008 Yang et al. 2010 23 CMP6 (JAK1, JAK3, TYK2) pyridone tetracycle 0.001 CTLL-2 B9 U266 KMS11 0.052-0.1 0.25 - - Thompson et al. 2002 Lucet et al. 2006 Pedranzini et al. 2008 24 13 sulfonamide aminoindazole 0.078 - - Antonysamy et al. 2009 25 comp 9 (JAK3,ALK, cKIT,GCK) polycyclic azaindole 0.001 TF-1-GMCSF (IC50) HT2-IL2 (IC50) 0.27 1.53 Wang et al. 2009 26 15a polycyclic azaindole 0.0008 TF-1-GMCSF (IC50) 0.16 Wang et al. 2010 27 40 (JAK3) aminopyrazolopyrimidine 0.0002 TF-1-GMCSF (IC50) HT2-IL2 (IC50) 0.16 3.2 Ledeboer et al. 2009 28 29 (JAK1,JAK3) pyrrolotriazine aminopyrrazole 0.0018 SET-2 0.11 Harikrishnan et al. 2011 29 atiprimod (JAK3) azaspirane - FDCP-EpoR,JAK2wt FDCP-EpoR,JAK2V617F SET-2 0.69 0.42 0.53 Hamasaki et al. 2005 Quintás-Cardama et al. 2011 30 G6 stilbenoid (diaryleten) 0.060 Ba/F3:EpoR,JAK2V617F HEL -
4.0 Kiss et al. 2009 Majumder et al. 2010 Kirabo et al. 2011 31 NVP-BSK805 (JAK1,TYK2,ABL) diarylquinoxaline 0.00048 0.00058 0.00056 Ba/F3:JAK2V617F SET-2 MB-02 UKE-1 MUTZ-8 0.039 0.051 0.064 0.071 0.331 Baffert et al. 2010 32 26 (ABL) diarylquinoxaline 0.0073 SET-2 0.088 Pissot-Soldermann et al. 2010 33 hexabromo cyclohexane hexabromo cyclohexane low mM g-2A - Sandberg et al. 2005 34 XL019 (JAK1,JAK3,FLT3, PDGFRB,cKIT) arylaminopyrimidine 0.002 HEL - Paquette et al. 2008 Shah et al. 2008 Forsyth et al. 2012 35 CEP33779 (JAK1,JAK3) triazolopyridine 0.0018 irf1-bla TF-1 (IC50) 0.061 Dugan et al. 2012 36 29 (JAK1,JAK3,TYK2) triazolopyridine 0.0017 SET-2 (IC50) 0.212 Siu et al. 2013 37 6 (JAK1,JAK3,TYK2) imidazopyrrolopyridine 0.0021 TF-1-EPO (IC50) 0.097 Zak et al. 2012 38 7 (JAK1,JAK3,TYK2) imidazopyrrolopyridine 0.0012 TF-1-EPO (IC50) 0.86 Kulagowski et al. 2012 39 31 (JAK1,JAK3,TYK2) imidazopyrrolopyridine 0.068 TF-1-EPO (IC50) 7.68 Zak et al. 2013 40 46 (JAK1,TYK2) pyridine amide 0.028 TF-1-EPO (IC50) 1.7 Liang et al. 2013 41 7j (JAK1,JAK3,TYK2) pyrazolopyrimidine 0.0001 SET-2 (IC50) TF-1-EPO (IC50) 0.0039 0.0074 Hanan et al. 2012 42 6 (JAK3) pyrazolopyrimidine amine 0.003 Ba/F3:TEL-JAK2 SET-2 UKE1 0.006 0.078 0.050 Guan et al. 2013 43 19a (JAK1,JAK3,CK2a2, KDR,ABL,FGR,TRKA,FLT4,FLT3,RET,ALK, FGFR1,AuroraA, LIMK1) methylimidazole 0.002 Ba/F3:TEL-JAK2 SET-2 UKE1 0.012 0.014 0.055 Su et al. 2014